Presentation of an Immunodominant Immediate-Early CD8+ T Cell Epitope Resists Human Cytomegalovirus Immunoevasion

PLoS Pathogens

Volumn 9, Issue 5, 2013, Pages

  Ameres, Stefanie ^a,b   Mautner, Josef ^b,c   Schlott, Fabian ^b,c   Neuenhahn, Michael ^b,c   Busch, Dirk H ^b,c   Plachter, Bodo ^d   Moosmann, Andreas ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b German Center for Infection Research   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE EVASION; NATURAL KILLER T CELL;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNE EVASION; KILLER CELLS, NATURAL; MALE; PROTEIN STRUCTURE, TERTIARY; RNA-BINDING PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 84878474103     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003383     Document Type: Article

References (79)

1. Boeckh M, Geballe AP, (2011) Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121: 1673-1680.
2. Crough T, Khanna R, (2009) Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 22: 76-98.
3. Quinnan GVJ, Kirmani N, Rook AH, Manischewitz JF, Jackson L, et al. (1982) Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307: 7-13.
4. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, et al. (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386.
5. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, et al. (2011) Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 51: 591-599.
6. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, et al. (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
7. Kenneson A, Cannon MJ, (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17: 253-276.
8. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256-1263.
9. Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, et al. (2012) A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12: 290-299.
10. Elkington R, Walker S, Crough T, Menzies M, Tellam J, et al. (2003) Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 77: 5226-5240.
11. Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, et al. (2005) Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 202: 673-685.
12. Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, et al. (2005) Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol 79: 2869-2879.
13. Stinski MF, Thomsen DR, Stenberg RM, Goldstein LC, (1983) Organization and expression of the immediate early genes of human cytomegalovirus. J Virol 46: 1-14.
14. Besold K, Plachter B, (2008) Recombinant viruses as tools to study human cytomegalovirus immune modulation. Med Microbiol Immunol 197: 215-222.
15. Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, et al. (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80: 10436-10456.
16. Jonjic S, del Val M, Keil GM, Reddehase MJ, Koszinowski UH, (1988) A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol 62: 1653-1658.
17. Reddehase MJ, Mutter W, Munch K, Buhring HJ, Koszinowski UH, (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61: 3102-3108.
18. Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, et al. (2005) Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036.
19. Sacre K, Nguyen S, Deback C, Carcelain G, Vernant JP, et al. (2008) Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol 82: 10143-10152.
20. Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, et al. (1999) Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73: 8179-8184.
21. Khan N, Cobbold M, Keenan R, Moss PA, (2002) Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis 185: 1025-1034.
22. Gilbert MJ, Riddell SR, Li CR, Greenberg PD, (1993) Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 67: 3461-3469.
23. Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, et al. (2004) Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104: 1075-1082.
24. Wang Z, La Rosa C, Mekhoubad S, Lacey SF, Villacres MC, et al. (2004) Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104: 847-856.
25. Ahn K, Angulo A, Ghazal P, Peterson PA, Yang Y, et al. (1996) Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc Natl Acad Sci U S A 93: 10990-10995.
26. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, et al. (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 84: 769-779.
27. Wiertz EJ, Tortorella D, Bogyo M, Yu J, Mothes W, et al. (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384: 432-438.
28. Gewurz BE, Wang EW, Tortorella D, Schust DJ, Ploegh HL, (2001) Human cytomegalovirus US2 endoplasmic reticulum-lumenal domain dictates association with major histocompatibility complex class I in a locus-specific manner. J Virol 75: 5197-5204.
29. Schust DJ, Tortorella D, Seebach J, Phan C, Ploegh HL, (1998) Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J Exp Med 188: 497-503.
30. Moosmann A, Khan N, Cobbold M, Zentz C, Delecluse HJ, et al. (2002) B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100: 1755-1764.
31. Wiesner M, Zentz C, Hammer MH, Cobbold M, Kern F, et al. (2005) Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. Eur J Immunol 35: 2110-2121.
32. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S, (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
33. Schmidt AH, Baier D, Solloch UV, Stahr A, Cereb N, et al. (2009) Estimation of high-resolution HLA-A,-B,-C,-DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70: 895-902.
34. Weekes MP, Wills MR, Mynard K, Carmichael AJ, Sissons JG, (1999) The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J Virol 73: 2099-2108.
35. Khan N, Best D, Bruton R, Nayak L, Rickinson AB, et al. (2007) T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 178: 4455-4465.
36. Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, et al. (2007) Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol 88: 1429-1439.
37. Besold K, Wills M, Plachter B, (2009) Immune evasion proteins gpUS2 and gpUS11 of human cytomegalovirus incompletely protect infected cells from CD8 T cell recognition. Virology 391: 5-19.
38. Holtappels R, Grzimek NK, Simon CO, Thomas D, Dreis D, et al. (2002) Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J Virol 76: 6044-6053.
39. Hesse J, Ameres S, Besold K, Krauter S, Moosmann A, et al. (2012) Suppression of CD8+ T cell recognition in the immediate-early phase of human cytomegalovirus infection. J Gen Virol 94: 376-86.
40. Noriega VM, Hesse J, Gardner TJ, Besold K, Plachter B, et al. (2012) Human cytomegalovirus US3 modulates destruction of MHC class I molecules. Mol Immunol 51: 245-253.
41. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70: 78-83.
42. Klages S, Ruger B, Jahn G, (1989) Multiplicity dependent expression of the predominant phosphoprotein pp65 of human cytomegalovirus. Virus Res 12: 159-168.
43. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD, (1996) Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383: 720-722.
44. Kalejta RF, (2008) Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 72: 249-65 table of contents.
45. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, et al. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89: 359-368.
46. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL, et al. (2001) Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci U S A 98: 6794-6799.
47. Schmolke S, Kern HF, Drescher P, Jahn G, Plachter B, (1995) The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture. J Virol 69: 5959-5968.
48. Barel MT, Pizzato N, Le Bouteiller P, Wiertz EJ, Lenfant F, (2006) Subtle sequence variation among MHC class I locus products greatly influences sensitivity to HCMV US2- and US11-mediated degradation. Int Immunol 18: 173-182.
49. Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, et al. (2003) Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. J Immunol 171: 6757-6765.
50. Holtappels R, Thomas D, Reddehase MJ, (2009) The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins. J Virol 83: 9611-9615.
51. Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, et al. (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 105: 3053-3058.
52. Holtappels R, Podlech J, Pahl-Seibert MF, Julch M, Thomas D, et al. (2004) Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues. J Exp Med 199: 131-136.
53. Kvale EO, Dalgaard J, Lund-Johansen F, Rollag H, Farkas L, et al. (2006) CD11c+ dendritic cells and plasmacytoid DCs are activated by human cytomegalovirus and retain efficient T cell-stimulatory capability upon infection. Blood 107: 2022-2029.
54. Arrode G, Boccaccio C, Lule J, Allart S, Moinard N, et al. (2000) Incoming human cytomegalovirus pp65 (UL83) contained in apoptotic infected fibroblasts is cross-presented to CD8(+) T cells by dendritic cells. J Virol 74: 10018-10024.
55. Lacey SF, Villacres MC, La Rosa C, Wang Z, Longmate J, et al. (2003) Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64: 440-452.
56. Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, et al. (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328: 102-106.
57. Jun Y, Kim E, Jin M, Sung HC, Han H, et al. (2000) Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules. J Immunol 164: 805-811.
58. Park B, Lee S, Kim E, Ahn K, (2003) A single polymorphic residue within the peptide-binding cleft of MHC class I molecules determines spectrum of tapasin dependence. J Immunol 170: 961-968.
59. Park B, Kim Y, Shin J, Lee S, Cho K, et al. (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20: 71-85.
60. Barel MT, Pizzato N, van Leeuwen D, Bouteiller PL, Wiertz EJ, et al. (2003) Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur J Immunol 33: 1707-1716.
61. Parham P, (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201-214.
62. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, et al. (2008) Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 41: 206-212.
63. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, et al. (2002) NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 169: 3257-3266.
64. Huard B, Fruh K, (2000) A role for MHC class I down-regulation in NK cell lysis of herpes virus-infected cells. Eur J Immunol 30: 509-515.
65. Llano M, Guma M, Ortega M, Angulo A, Lopez-Botet M, (2003) Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol 33: 2744-2754.
66. Carr WH, Little AM, Mocarski E, Parham P, (2002) NK cell-mediated lysis of autologous HCMV-infected skin fibroblasts is highly variable among NK cell clones and polyclonal NK cell lines. Clin Immunol 105: 126-140.
67. Cerboni C, Mousavi-Jazi M, Linde A, Soderstrom K, Brytting M, et al. (2000) Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol 164: 4775-4782.
68. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, et al. (1998) Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 187: 1681-1687.
69. Adnan S, Balamurugan A, Trocha A, Bennett MS, Ng HL, et al. (2006) Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 108: 3414-3419.
70. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, et al. (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
71. Thomas R, Apps R, Qi Y, Gao X, Male V, et al. (2009) HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 41: 1290-1294.
72. Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, et al. (2007) HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Tissue Antigens 70: 455-463.
73. Schub A, Schuster IG, Hammerschmidt W, Moosmann A, (2009) CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 183: 6819-6830.
74. Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, et al. (2008) Conditional immortalization of human B cells by CD40 ligation. PLoS ONE 3: e1464.
75. Falk CS, Steinle A, Schendel DJ, (1995) Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells. J Exp Med 182: 1005-1018.
76. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ, (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751-1767.
77. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, et al. (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569-7579.
78. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, et al. (2002) Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 8: 631-637.
79. Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, et al. (2007) Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 320: 119-131.